Group 1 - Huhtamaki has appointed Axel Glade as President of the Flexible Packaging segment, effective July 1, 2025, earlier than previously announced [1] - Axel Glade will report to Ralf K. Wunderlich, the President & CEO, and will be based in Espoo, Finland [1] - Glade joins Huhtamaki from Constantia Flexibles, where he served as Executive Vice President of the Film Division [1] Group 2 - The Global Executive Team will include Ralf K. Wunderlich (Chair), Fredrik Davidsson, Sara Engber, Thomas Geust, Axel Glade, Ann O'Hara, Sami Pauni, Johan Rabe, Ingolf Thom, and Changsheng Wu [2] - Huhtamaki is a leading global provider of sustainable packaging solutions, focusing on hygiene, safety, accessibility, affordability, and food waste prevention [3] - The company has over 100 years of history, operates in 36 countries with around 18,000 professionals, and reported net sales of EUR 4.1 billion in 2024 [4]

今天分享的是：中国高端手机影像趋势与用户洞察-知乎研究院 报告共计：5页 《中国高端手机影像趋势与用户洞察-知乎研究院》显示，手机已成为影像爱好者的核心设备，77.2%用户以手机为主力拍摄工具，71.8%每日用手机记录生 活，27%会分享至社媒。用户摄影水平提升，61.3%常切换拍摄模式和参数，专业影像组更注重分享与创作，手机影像组则侧重个人记录。拍摄题材以风 光、人文、人像为主，手机用户常用24-26mm默认焦段，专业用户更偏好35mm焦段。后期处理中，50%用户在手机完成修图，但专业用户耗时更久，53% 对手机后期功能有更高期待。 用户认为手机影像在对焦速度、场景感光、运动抓拍等方面存在不足，43.1%认可高端影像手机可部分替代专业设备，但专业用户认为手机操作复杂。选购 高端手机时，影像能力是基础门槛，用户关注硬件配置（如潜望式长焦、多光谱传感器）、AI功能（自动修图、创意创作）及便携性，40%愿将高端影像手 机作为副机。 未来趋势上，AI深度融入影像全流程，用户期待AI在画质提升、拍摄辅助等方面突破，64.2%期望3D/AR影像交互，46.8%关注可变光圈。超半数用户认为 顶级影像赛事接纳手机作品将是行 ...

[Music] Japan is having fewer babies than ever [Music] before. Meanwhile, the number of very elderly people is at a record high. This year brings the country to a tipping point known as the 2025 problem with Japan's huge postwar baby boom generation now all in their mid to late 70s.When it comes to living with a shrinking and aging population, the data clearly shows that Japan is ahead of other countries, but also that its path isn't unique, and neither are the potential solutions. So, the rest of the world ...

Core Insights - Genmab A/S will present new research from its late-stage portfolio at the 2025 ASCO Annual Meeting from May 30 to June 3 in Chicago, Illinois [1] - The presentations will include results from a Phase 1/2 trial of rinatabart sesutecan (Rina-S) for recurrent/advanced endometrial cancer and long-term follow-up data from the EPCORE NHL-1 study of epcoritamab in relapsed/refractory diffuse large B-cell lymphoma [2][8] Company Commitment - Genmab emphasizes its commitment to advancing antibody science for patients needing alternative treatment options, particularly for endometrial cancers with rising mortality rates [3] - The company is encouraged by Rina-S as a potential treatment option for endometrial cancer and continues to evaluate epcoritamab as a core therapy across B-cell malignancies in collaboration with AbbVie [3][15] Event Details - Genmab will host a virtual review of the Rina-S data presented at ASCO on June 2 at 4:00 PM CDT, with details available on their investor relations website [4] Abstracts and Presentations - Abstracts accepted for presentation at ASCO include key studies on Rina-S and epcoritamab, with specific presentation times outlined [5][7]

SHENZHEN, China, May 22, 2025 (GLOBE NEWSWIRE) -- MicroCloud Hologram Inc. (NASDAQ: HOLO), (“HOLO” or the "Company"), a technology service provider, they announced significant progress in the field of quantum-enhanced imaging based on nonlocal effects. This achievement has not only been validated in a laboratory setting but has also demonstrated advantages over traditional imaging in practical technical implementations. Compared to conventional phase imaging systems, HOLO leverages quantum-enhanced holograp ...

Since launching pep+ in September 2021, PepsiCo has made significant progress on regenerative agriculture and water stewardship and positive strides on sustainable packaging and climate change, while accounting for external realities and business growth. "As circumstances evolve, PepsiCo continually adapts how we source ingredients; make, move, and sell our products; and inspire people through our brands," said PepsiCo Chairman and Chief Executive Officer Ramon Laguarta. "This journey is underpinned by pep+ ...

21 May 2025 | 4:01PM EDT What's Top of Mind in Macro Research: Growing US fiscal concerns, tracking trade flows, the positives of population aging Transcript US: fiscal concerns grow We estimate that the House Republican reconciliation package that extends expiring tax cuts, enacts new tax cuts, and reduces spending will increase the US deficit by around $275bn, or 0.8% of GDP, next year compared with current policy. This increase is slightly larger than we originally anticipated, mainly owing to more gener ...

Core Viewpoint - Meta Platforms is experiencing a positive trend in analyst upgrades, with nearly 20 analysts raising their price targets following the latest earnings report, indicating strong market confidence in the company's growth potential [1] Group 1: Analyst Ratings and Price Targets - Wolfe Research has set a new price target of $750 for Meta, suggesting an upside of nearly 18% from its May 20 closing price [2] - The average price target for Meta is currently $701.05, with a high forecast of $935.00 and a low forecast of $525.00, reflecting a moderate buy rating based on 44 analyst ratings [9] Group 2: Business Messaging Opportunities - Mark Zuckerberg highlighted business messaging as a key growth opportunity, with Wolfe estimating it could represent a $30–$40 billion market for Meta [3][8] - Currently, Meta generates approximately $1.5 billion to $2 billion in annual revenue from WhatsApp, which is part of the Other Family of Apps Revenue that totaled around $1.8 billion over the last 12 months [7] Group 3: User Engagement and Market Potential - WhatsApp boasts over 3 billion monthly active users, equating to about 38% of the global population, while Facebook Messenger has over one billion monthly users [5] - The potential for business messaging could lead to a 20x increase in revenue, with $35 billion in business messaging revenue representing over 20% of Meta's total revenue of $170 billion in the last 12 months [8] Group 4: AI Integration and Monetization Strategy - Meta plans to leverage AI to enhance the monetization of business messaging, envisioning an "AI business agent" for customer service and sales campaigns [9] - The company is currently testing AI features for business messaging, which could improve profitability in developed markets despite the low labor costs in emerging economies [11][12]

Core Viewpoint - Longevity Health Holdings, Inc. has received approval from the Nasdaq Hearings Panel to continue its listing on Nasdaq, contingent upon meeting initial listing rules following its proposed merger with 20/20 BioLabs by September 2, 2025 [1][3]. Company Overview - Longevity Health Holdings focuses on extending human longevity and healthy aging through innovative products in regenerative bio-aesthetics, diagnostics, and nutrition [1][4]. - The company offers two regenerative technologies: Carmell Secretome™ and Elevai Exosomes™, aimed at improving skin and hair health [4]. Merger Details - The proposed merger with 20/20 BioLabs includes a strategic plan to effect a 1-for-30 reverse stock split to meet Nasdaq's listing requirements [2]. - The S-4 registration statement for the merger was filed on May 8, 2025, and the reverse stock split was executed on May 12, 2025 [2]. 20/20 BioLabs Overview - 20/20 BioLabs specializes in developing innovative laboratory tests for early detection and management of chronic disease risks, including a multi-cancer early detection blood test available in the U.S. [5]. - The company plans to introduce a new blood test for monitoring chronic inflammation, which is linked to several leading causes of death in America [5].

Summary of Karyopharm Therapeutics (KPTI) Conference Call Company Overview - **Company**: Karyopharm Therapeutics (KPTI) - **Key Products**: Selinexor (XPOVIO) - **Focus Areas**: Oncology, specifically multiple myeloma and myelofibrosis Key Points Commercial Performance and Product Dynamics - **Q1 Demand Growth**: KPTI reported a 5% year-over-year demand growth for XPOVIO in Q1, despite a one-time impact of $5 million from atypical returns related to high-dose selinexor [3][4] - **Real-World Utilization**: The company is focusing on increasing the utilization of selinexor in both community and academic settings, with a particular emphasis on lower doses [4][5] - **Community Treatment**: Selinexor is primarily used in the community setting for multiple myeloma patients, positioned in the second to fourth line of treatment [5][6] Growth Drivers and Future Outlook - **T Cell Engaging Therapies**: KPTI is generating data to support the use of selinexor in conjunction with T cell engaging therapies, which are becoming more prevalent in earlier treatment lines [9][10] - **Myelofibrosis Opportunity**: The ongoing SENTRI trial is evaluating selinexor in combination with ruxolitinib, with promising early data showing a 79% SVR 35 rate at week 24 compared to 30-35% for ruxolitinib alone [12][13][15] - **Durability of Response**: The company reported a 100% durability of response for patients achieving SVR 35 or TSS 50, indicating sustained benefits from treatment [17] Clinical Trials and Data - **Phase III Trials**: KPTI is focused on executing its Phase III trials for both myelofibrosis and endometrial cancer, with the latter leveraging a biomarker (p53 wild type) for patient selection [45][46] - **Endpoint Changes**: The transition from TSS 50 to absolute TSS is seen as a more sensitive measure for symptom improvement, gaining positive feedback from investigators and regulators [28][29] Safety and Tolerability - **Antiemetic Use**: KPTI has incorporated dual antiemetics in its Phase III trials to mitigate nausea and vomiting, achieving over 85% compliance and lower rates of these side effects [36][38] - **Safety Profile**: The safety profile of selinexor is evolving positively, with improvements noted in gastrointestinal side effects [17][38] Commercial Strategy - **Market Positioning**: KPTI aims to target all frontline myelofibrosis patients, leveraging existing commercial infrastructure to facilitate rapid uptake among physicians [41][42] - **Unmet Need**: Research indicates a significant unmet need in the myelofibrosis market, with 75% of physicians willing to adopt therapies that address key disease hallmarks [42] Financial Discipline - **Operational Focus**: KPTI is maintaining a disciplined approach to operational expenditures, concentrating resources on Phase III readouts and shutting down non-essential programs [48][49] Additional Insights - **Endometrial Cancer Landscape**: The company anticipates that selinexor will address a sizable unmet need in patients with p53 wild type tumors, with enrollment for the Phase III trial progressing well [46][47] - **Future Readouts**: KPTI is positioned for significant upcoming data readouts that could transform treatment paradigms in both myelofibrosis and endometrial cancer [49]